SB719,31,88 b. A description of how to access insulin through a patient assistance program.
SB719,31,109 c. Information on how to contact a navigator for assistance in accessing insulin
10through an urgent need safety net program or patient assistance program.
SB719,31,1211 d. Information on how to contact the commissioner if a manufacturer
12determines that an individual is not eligible for a patient assistance program.
SB719,31,1413 e. A notification that an individual may contact the commissioner for more
14information or assistance in accessing ongoing affordable insulin options.
SB719,31,2115 (c) Navigators. The commissioner shall develop a training program to provide
16navigators with information and the resources necessary to assist individuals in
17accessing appropriate long-term insulin options. The commissioner shall compile
18a list of navigators that have completed the training program and are available to
19assist individuals in accessing affordable insulin coverage options. The list shall be
20made available on the office's website and to pharmacies and health care
21practitioners who dispense and prescribe insulin.
SB719,32,222 (d) Satisfaction surveys. 1. The commissioner shall develop and conduct a
23satisfaction survey of individuals who have accessed insulin through urgent need
24safety net programs and patient assistance programs. The survey shall ask whether
25the individual is still in need of a long-term solution for affordable insulin and shall

1include questions about the individual's satisfaction with all of the following, if
2applicable:
SB719,32,33 a. Accessibility to urgent-need insulin.
SB719,32,54 b. Adequacy of the information sheet and list of navigators received from the
5pharmacy.
SB719,32,66 c. Helpfulness of a navigator.
SB719,32,87 d. Ease of access in applying for a patient assistance program and receiving
8insulin from the pharmacy under the patient assistance program.
SB719,32,129 2. The commissioner shall develop and conduct a satisfaction survey of
10pharmacies that have dispensed insulin through urgent need safety net programs
11and patient assistance programs. The survey shall include questions about the
12pharmacy's satisfaction with all of the following, if applicable:
SB719,32,1413 a. Timeliness of reimbursement from manufacturers for insulin dispensed by
14the pharmacy under urgent need safety net programs.
SB719,32,1515 b. Ease in submitting insulin orders to manufacturers.
SB719,32,1616 c. Timeliness of receiving insulin orders from manufacturers.
SB719,32,1817 3. The commissioner may contract with a nonprofit entity to develop and
18conduct the surveys under subds. 1. and 2. and to evaluate the survey results.
SB719,32,2119 4. No later than July 1, 2026, the commissioner shall submit to the governor
20and the chief clerk of each house of the legislature, for distribution to the legislature
21under s. 13.172 (2), a report on the results of the surveys under subds. 1. and 2.
SB719,33,2 22(9) Penalty. A manufacturer that fails to comply with this section may be
23assessed a penalty of up to $200,000 per month of noncompliance, with the maximum
24penalty increasing to $400,000 per month if the manufacturer continues to be in

1noncompliance after 6 months and increasing to $600,000 per month if the
2manufacturer continues to be in noncompliance after one year.
SB719,18 3Section 18 . 632.869 of the statutes is created to read:
SB719,33,5 4632.869 Reimbursement to federal drug pricing program participants.
5(1) In this section:
SB719,33,96 (a) “Covered entity” means an entity described in 42 USC 256b (a) (4) (A), (D),
7(E), (J), or (N) that participates in the federal drug pricing program under 42 USC
8256b
, a pharmacy of the entity, or a pharmacy contracted with the entity to dispense
9drugs purchased through the federal drug pricing program under 42 USC 256b.
SB719,33,1010 (b) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).
SB719,33,12 11(2) No person, including a pharmacy benefit manager and 3rd-party payer,
12may do any of the following:
SB719,33,1613 (a) Reimburse a covered entity for a drug that is subject to an agreement under
1442 USC 256b at a rate lower than that paid for the same drug to pharmacies that are
15not covered entities and have a similar prescription volume to that of the covered
16entity.
SB719,33,1917 (b) Assess a covered entity any fee, charge back, or other adjustment on the
18basis of the covered entity's participation in the federal drug pricing program under
1942 USC 256b.
SB719,19 20Section 19 . 632.895 (6) (title) of the statutes is amended to read:
SB719,33,2121 632.895 (6) (title) Equipment and supplies for treatment of diabetes; insulin.
SB719,20 22Section 20 . 632.895 (6) of the statutes is renumbered 632.895 (6) (a) and
23amended to read:
SB719,34,924 632.895 (6) (a) Every disability insurance policy which that provides coverage
25of expenses incurred for treatment of diabetes shall provide coverage for expenses

1incurred by the installation and use of an insulin infusion pump, coverage for all
2other equipment and supplies, including insulin or any other prescription
3medication, used in the treatment of diabetes, and coverage of diabetic
4self-management education programs. Coverage Except as provided in par. (b),
5coverage
required under this subsection shall be subject to the same exclusions,
6limitations, deductibles, and coinsurance provisions of the policy as other covered
7expenses, except that insulin infusion pump coverage may be limited to the purchase
8of one pump per year and the insurer may require the insured to use a pump for 30
9days before purchase.
SB719,21 10Section 21 . 632.895 (6) (b) of the statutes is created to read:
SB719,34,1111 632.895 (6) (b) 1. In this paragraph:
SB719,34,1312 a. “Cost sharing” means the total of any deductible, copayment, or coinsurance
13amounts imposed on a person covered under a policy or plan.
SB719,34,1414 b. “Self-insured health plan” has the meaning given in s. 632.85 (1) (c).
SB719,34,1715 2. Every disability insurance policy and self-insured health plan that covers
16insulin and imposes cost sharing on prescription drugs may not impose cost sharing
17on insulin in an amount that exceeds $35 for a one-month supply of insulin.
SB719,34,2218 3. Nothing in this paragraph prohibits a disability insurance policy or
19self-insured health plan from imposing cost sharing on insulin in an amount less
20than the amount specified under subd. 2. Nothing in this paragraph requires a
21disability insurance policy or self-insured health plan to impose any cost sharing on
22insulin.
SB719,22 23Section 22 . Nonstatutory provisions.
SB719,35,3
1(1) Centralized drug repository. The department of health services shall
2study and implement a centralized physical drug repository program under s.
3255.056.
SB719,35,104 (2) Prescription drug importation program. The commissioner of insurance
5shall submit the first report required under s. 601.575 (5) by the next January 1 or
6July 1, whichever is earliest, that is at least 180 days after the date the prescription
7drug importation program is fully operational under s. 601.575 (4). The
8commissioner of insurance shall include in the first 3 reports submitted under s.
9601.575 (5) information on the implementation of the audit functions under s.
10601.575 (1) (n).
SB719,35,1311 (3) Prescription drug purchasing entity. During the 2023-2025 fiscal
12biennium, the office of the commissioner of insurance shall conduct a study on the
13viability of creating or implementing a state prescription drug purchasing entity.
SB719,23 14Section 23. Effective date.
SB719,35,1815 (1) Cost-sharing cap on insulin. The treatment of ss. 609.83 and 632.895 (6)
16(title), the renumbering and amendment of s. 632.895 (6), and the creation of s.
17632.895 (6) (b) take effect on the first day of the 4th month beginning after
18publication.
SB719,35,1919 (End)
Loading...
Loading...